AT
AN2 Therapeutics, Inc.
SEC filingPharmaceuticals · Menlo Park, CA
Amount raised$40Msold at filing
Total offering$40M
Investors in the raise16count reported to the SEC
FiledMar 25, 2026first sale Mar 10, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Margaret Lynn FitzPatrickDirector
Patricia Lynn MartinDirector
Melvin Lynn SpigelmanDirector
Gilbert Lynn MarksDirector
Stephanie Lynn WongDirector
Joseph S. ZakrzewskiDirector
Joshua EizenExecutive Officer
Kabeer S. AzizDirector
Rob S. ReadnourDirector
Sanjay ChandaExecutive Officer
Lucy DayExecutive Officer
Eric EasomExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.